ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL850
CHEMBL850
Compound Name SPARFLOXACIN
ChEMBL Synonyms CI-978 | Spara | SPARFLOXACIN | ZAGAM | AT-4140
Max Phase 4 (Approved)
Withdrawn Yes
Trade Names Spara | ZAGAM
Molecular Formula C19H22F2N4O3

Additional synonyms for CHEMBL850 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES C[C@@H]1CN(C[C@H](C)N1)c2c(F)c(N)c3C(=O)C(=CN(C4CC4)c3c2F)C( ...
Download SMILES
Standard InChI InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12 ...
Download InChI
Standard InChI Key DZZWHBIBMUVIIW-DTORHVGOSA-N

Sources

  • AstraZeneca Deposited Data
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification
  • Withdrawn Drugs

Alternate Forms of Compound in ChEMBL


CHEMBL850

Molecule Features

CHEMBL850 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Withdrawn

Withdrawal Information

Year 2001
Country United States
Reason QT prolongation and phototoxicity
Class Cardiotoxicity; Dermatological toxicity

Mechanism of Action

Mechanism of Action ChEMBL Target References
Bacterial DNA gyrase inhibitor Bacterial DNA gyrase FDA
Topoisomerase IV inhibitor Topoisomerase IV FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
OsteomyelitisD010019EFO:0003102osteomyelitis0ClinicalTrials

Clinical Data

ClinicalTrials.gov SPARFLOXACIN
The Cochrane Collaboration SPARFLOXACIN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL850. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


10uM


ChEMBL_ID Target Name Organism Score
CHEMBL4088 Topoisomerase IV subunit A Staphylococcus aureus 1.000

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
392.4 392.166 2.08 3 100.59 ZWITTERION


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 3 0 7 4 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
6.42 8.59 2.6 .83 2 28 0.69

Structural Alerts

There are 5 structural alerts for CHEMBL850. To view alerts please click here.

Compound Cross References

ATC J - ANTIINFECTIVES FOR SYSTEMIC USE
J01 - ANTIBACTERIALS FOR SYSTEMIC USE
J01M - QUINOLONE ANTIBACTERIALS
J01MA - Fluoroquinolones
J01MA09 - sparfloxacin

ChemSpider ChemSpider:DZZWHBIBMUVIIW-DTORHVGOSA-N
PubChem SID: 144205133 SID: 26719819 SID: 29218052
Wikipedia Sparfloxacin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL850



ACToR 110871-86-8
BindingDB 50366822
Brenda 2250
ChEBI 9212
DrugBank DB01208
DrugCentral 2466
eMolecules 499196
EPA CompTox Dashboard DTXSID9023590
FDA SRS Q90AGA787L
Human Metabolome Database HMDB0015339
IBM Patent System C6813164654A27B766139D31E95A95F9
KEGG Ligand C07662
LINCS LSM-5251
Mcule MCULE-1827276157
MolPort MolPort-002-507-759
Nikkaji J324.247A
PharmGKB PA451472
PubChem 60464 6956367
PubChem: Drugs of the Future 12014309
PubChem: Thomson Pharma 14830034 16618671
Selleck sparfloxacin
SureChEMBL SCHEMBL41311
ZINC ZINC000000538362

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/DZZWHBIBMUVIIW-DTORHVGOSA-N spacer
spacer